Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Sana Biotechnology’s investigational allogeneic islet cell therapy has survived and secreted insulin for more than one year ...

SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind ...

USANewsGroup.com News Commentary-- The global cell therapy manufacturing market is hitting a pivotal inflection point. It's ...

Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, ...

Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement ...

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and ...

EUDA Health (EUDA) announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. to form a joint venture. Guangdong Cell Biotech develops autologous cell treatments and ...

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

Announcement of a podium presentation at a prestigious symposium, showcasing innovative research in cell therapy for type 1 diabetes. Presentation features promising clinical data on UP421, a novel ...

When researchers revealed the results of a study on the prevalence of microplastics in human placentas earlier this year, the findings were profoundly disturbing. Researchers analysed 62 placental ...